[go: up one dir, main page]

HK1124793A1 - Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules - Google Patents

Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules

Info

Publication number
HK1124793A1
HK1124793A1 HK09103674.8A HK09103674A HK1124793A1 HK 1124793 A1 HK1124793 A1 HK 1124793A1 HK 09103674 A HK09103674 A HK 09103674A HK 1124793 A1 HK1124793 A1 HK 1124793A1
Authority
HK
Hong Kong
Prior art keywords
adsorbents
alone
site
combination
intestinal delivery
Prior art date
Application number
HK09103674.8A
Other languages
English (en)
Chinese (zh)
Inventor
Helene Huguet
Antoine Andremont
Nicolas Tsapis
Elias Fattal
Original Assignee
Da Volterra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Da Volterra filed Critical Da Volterra
Publication of HK1124793A1 publication Critical patent/HK1124793A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/44—Elemental carbon, e.g. charcoal, carbon black
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK09103674.8A 2006-05-17 2009-04-21 Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules HK1124793A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80112106P 2006-05-17 2006-05-17
PCT/EP2007/054831 WO2007132022A2 (en) 2006-05-17 2007-05-18 Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules

Publications (1)

Publication Number Publication Date
HK1124793A1 true HK1124793A1 (en) 2009-07-24

Family

ID=38521276

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09103674.8A HK1124793A1 (en) 2006-05-17 2009-04-21 Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules

Country Status (15)

Country Link
US (2) US8048413B2 (da)
EP (2) EP2386308B1 (da)
JP (1) JP5829003B2 (da)
CN (2) CN101969964A (da)
AU (1) AU2007251565B2 (da)
BR (1) BRPI0712098B8 (da)
CA (1) CA2651569C (da)
DK (2) DK2026823T3 (da)
ES (2) ES2660234T3 (da)
HK (1) HK1124793A1 (da)
HU (1) HUE036492T2 (da)
PL (2) PL2026823T3 (da)
PT (2) PT2386308T (da)
TR (1) TR201802214T4 (da)
WO (1) WO2007132022A2 (da)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1883396B1 (en) * 2005-05-18 2013-07-03 DA Volterra Colonic delivery of adsorbents
US8048413B2 (en) 2006-05-17 2011-11-01 Helene Huguet Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules
US20080124279A1 (en) * 2006-11-17 2008-05-29 Antoine Andremont Colonic delivery using Zn/pectin beads with a Eudragit coating
US8273376B2 (en) * 2006-11-17 2012-09-25 Da Volterra Colonic delivery of metallo-dependent enzymes
FR2950252B1 (fr) * 2009-09-23 2012-01-20 Centre Nat Rech Scient Forme galenique capable d'adsorber de maniere specifique les molecules indesirables
WO2011104275A1 (en) 2010-02-23 2011-09-01 Da Volterra Formulations for oral delivery of adsorbents in the gut
CN107260755A (zh) * 2010-04-01 2017-10-20 西托索尔本茨公司 治疗炎症的方法
JP5889321B2 (ja) 2010-11-04 2016-03-22 アルビレオ アクチエボラグ 肝疾患の処置用のｉｂａｔ阻害剤
GB201204696D0 (en) 2012-03-16 2012-05-02 Ucl Business Plc Therapy
GB201212866D0 (en) * 2012-07-20 2012-09-05 Formac Pharmaceuticals Nv Dry granulates of mesoporous silica powders
WO2014037877A1 (en) 2012-09-04 2014-03-13 Irccs Materno-Infantile Burlo Garofolo - Ospedale Di Alta Specializzazione E Di Rilievo Nazionale Per La Salute Della Donna E Del Bambino Food product or a seasoning thereof containing bentonite or montmorillonite having activity of metabolic protein load reduction
CA2885278A1 (en) * 2012-09-21 2014-03-27 Ferring B.V. Pharmaceutical composition
CN113842362A (zh) 2012-11-14 2021-12-28 格雷斯公司 含有生物活性材料与无序无机氧化物的组合物
US11931227B2 (en) 2013-03-15 2024-03-19 Cook Medical Technologies Llc Bimodal treatment methods and compositions for gastrointestinal lesions with active bleeding
EP2978413A1 (en) 2013-03-25 2016-02-03 Ferring BV Composition for the treatment of disease
CN103521173A (zh) * 2013-10-12 2014-01-22 东北农业大学 能够吸附饲料中玉米赤霉烯酮的吸附剂及其制备方法
JP6751020B2 (ja) 2014-06-25 2020-09-02 Ｅａファーマ株式会社 固形製剤及びその着色防止又は着色低減方法
US10674746B2 (en) 2015-10-27 2020-06-09 Cytozyme Animal Nutrition, Inc. Animal nutrition compositions and related methods
CN108473384A (zh) 2015-10-27 2018-08-31 细胞酶动物营养品公司 动物营养成分及相关方法
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
CN105920587A (zh) * 2016-05-12 2016-09-07 扬州大学 一种pH敏感型的胰岛素缓释口服制剂及其制备方法
US10231903B2 (en) 2016-11-10 2019-03-19 Medisca Pharmaceutique Inc. Pharmaceutical compounding methods and systems
WO2018131930A1 (ko) * 2017-01-12 2018-07-19 차장옥 콕시듐증 예방 또는 치료용 조성물, 이의 제조방법 및 이의 이용
US10972203B2 (en) * 2017-06-12 2021-04-06 Gracenote, Inc. Detecting and responding to rendering of interactive video content
CA3071285A1 (en) 2017-08-09 2019-02-14 Albireo Ab Cholestyramine granules, oral cholestyramine formulations and use thereof
CN112449637B (zh) 2018-06-05 2024-03-19 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
MX2020013839A (es) 2018-06-20 2021-03-25 Albireo Ab Formulacion farmaceutica de odevixibat.
JP2021534091A (ja) 2018-08-05 2021-12-09 ダ・ヴォルテッラ 抗がん剤の有効性を改善する方法
MX2021001393A (es) 2018-08-05 2021-04-12 Da Volterra Composiciones para el tratamiento de la enfermedad de injerto contra huesped.
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
PT3921028T (pt) 2019-02-06 2023-02-15 Albireo Ab Compostos de benzotiadiazepina e a sua utilização como moduladores de ácido biliar
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
EP4069361B1 (en) 2019-12-04 2024-01-03 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
CN114761018A (zh) 2019-12-04 2022-07-15 阿尔比里奥公司 苯并硫杂二氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
CR20220315A (es) 2019-12-04 2022-10-26 Albireo Ab Compuestos de benzoti(di)azepina y su uso como moduladores del ácido biliar
CA3158276A1 (en) 2019-12-04 2021-06-10 Per-Goran Gillberg Benzothia(di)azepine compounds and their use as bile acid modulators
ES3002777T3 (en) 2020-08-03 2025-03-07 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
WO2022084550A1 (en) 2020-10-23 2022-04-28 Da Volterra Compositions for use in the treatment or prevention of dysbiosis
WO2022090433A1 (en) 2020-10-30 2022-05-05 Da Volterra Method for the manufacture of an adsorbent formulation
KR20230106651A (ko) 2020-11-12 2023-07-13 알비레오 에이비 진행성 가족성 간내 담즙정체증(pfic)을 치료하기 위한 오데빅시바트
WO2022101267A2 (en) 2020-11-12 2022-05-19 Da Volterra Compositions for delivery of an adsorbent
WO2022101269A1 (en) 2020-11-13 2022-05-19 Da Volterra Formulations and dosage regimen for oral delivery of adsorbents in the gut
JP2024500309A (ja) 2020-12-04 2024-01-09 アルビレオ エービー ベンゾチア（ジ）アゼピン化合物および胆汁酸モジュレータとしてのその使用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2437878A1 (de) 1974-07-26 1976-02-12 Sandoz Ag Ueberzogene aktivkohleteilchen
US5597564A (en) 1986-08-28 1997-01-28 Enzacor Properties Limited Method of administering a microgranular preparation to the intestinal region of animals
JPH03120227A (ja) * 1989-10-02 1991-05-22 Shigeo Ochi 飲食物消化分解産物吸収抑制剤
US5484773A (en) 1994-02-14 1996-01-16 Alberta Research Council Treatment of antibiotic associated diarrhea
JP2561228B2 (ja) * 1994-05-27 1996-12-04 呉羽化学工業株式会社 抗炎症性腸疾患剤
WO1998003260A1 (en) * 1996-07-22 1998-01-29 Kouki Bussan Yugenkaisha Novel adsorbent
US5827497A (en) * 1996-08-14 1998-10-27 Mayo Foundation For Medical Education And Research Charcoal-radionuclide agents for measurement of gastrointestinal transit
ATE430477T1 (de) * 1996-10-16 2009-05-15 Napo Pharmaceuticals Inc Enteral-formulierungen von proanthocyanidzusammensetzungen gegen diarrhöe
US5929051A (en) 1998-05-13 1999-07-27 Carrington Laboratories, Inc. Aloe pectins
JP5068401B2 (ja) 1998-09-28 2012-11-07 カプスゲル・ベルギウム・ナムローゼ・フェンノートシャップ Ｈｐｍｃカプセルを使用する腸及び結腸への送達
WO2000047062A2 (en) * 1999-02-01 2000-08-17 Shaman Pharmaceuticals, Inc. Enteric formulations of proanthocyanidin polymer dietary supplements and methods for preparing same
US6706287B2 (en) 2001-05-15 2004-03-16 Kibow Biotech Inc. Prebiotic and probiotic compositions and methods for their use in gut-based therapies
US6706263B2 (en) 1999-04-30 2004-03-16 Kibow Biotech Inc. Composition for alleviating symptoms of uremia in patients
US6262085B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6991807B2 (en) 2000-02-24 2006-01-31 Advancis Pharmaceutical, Corp. Antibiotic composition
DE10013029A1 (de) * 2000-03-17 2001-09-20 Roehm Gmbh Mehrschichtige Arzneiform für die Colonfreigabe
CN1326745A (zh) 2000-06-01 2001-12-19 翟永功 蒙脱石为胃肠道药物的成份
US7157095B2 (en) 2000-10-13 2007-01-02 Advancis Pharmaceutical Corporation Multiple-delayed release antifungal product, use and formulation thereof
US7105174B2 (en) 2000-10-13 2006-09-12 Advancis Pharmaceutical Corporation Multiple-delayed release anti-neoplastic product, use and formulation thereof
US7074417B2 (en) 2000-10-13 2006-07-11 Advancis Pharmaceutical Corporation Multiple-delayed release anti-viral product, use and formulation thereof
ES2298236T3 (es) 2001-01-31 2008-05-16 Evonik Rohm Gmbh Forma medicamentosa de particulas multiples, que contiene por lo menos dos formas de granulos, revestidas de manera diferente.
JP2002308786A (ja) * 2001-04-12 2002-10-23 Oto Corporation:Kk 食物繊維で包括されたカーボン粒入りゼリーの製造法
MXPA04003540A (es) 2001-10-15 2004-07-22 R Hm Gmbh & Co Kg Utilizacion de un copolimero para producir una forma galenica que contiene un peptido o proteina como agente activo.
AU2002359768A1 (en) 2001-12-20 2003-10-27 Middlebrook Pharmaceuticals, Inc. Antibiotic product, use and formulation thereof
WO2003075852A2 (en) 2002-03-07 2003-09-18 Advancis Pharmaceuticals Corporation Antibiotic composition
DE10214002A1 (de) 2002-03-27 2003-10-09 Roehm Gmbh Pharmazeutische Formulierung für den Wirkstoff Budesonid
AU2003240545A1 (en) 2002-06-06 2003-12-22 Therapeutics Corporation Genome Use of ramoplanin to treat diseases associated with the use of antibiotics
FR2843302B1 (fr) 2002-08-09 2004-10-22 Centre Nat Rech Scient Forme galenique pour la delivrance colique de principes actifs
SE0203065D0 (sv) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
DE10250543A1 (de) 2002-10-29 2004-05-19 Röhm GmbH & Co. KG Mehrschichtige Arzneiform
DE10260921A1 (de) 2002-12-20 2004-07-01 Röhm GmbH & Co. KG Verfahren zum Überziehen von Substraten für pharmazeutische Anwendungen mit einem Gemisch aus zwei filmbildenden Überzugsmitteln
DE10332160A1 (de) 2003-07-15 2005-02-03 Röhm GmbH & Co. KG Multipartikuläre Arzneiform, enthaltend mucoadhaesiv formulierte Peptid- oder Protein-Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform
AR045068A1 (es) 2003-07-23 2005-10-12 Univ Missouri Formulacion de liberacion inmediata de composiciones farmaceuticas
MY147202A (en) * 2003-11-26 2012-11-14 Novartis Ag Compositions comprising organic compounds
AU2004296877A1 (en) 2003-12-09 2005-06-23 Incyte Corporation Dosing methods for ss-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine antiviral therapy
ES2271714T3 (es) * 2004-02-20 2007-04-16 Cum Pharma Consulting Anstalt Composicion farmaceutica para aplicacion oral y procedimiento de preparacion de la misma.
DE102004035938A1 (de) 2004-07-23 2006-02-16 Röhm GmbH & Co. KG Verfahren zur Herstellung von überzogenen Arzneiformen mit stabilem Wirkstofffreigabeprofil
DE102004036437A1 (de) 2004-07-27 2006-03-23 Röhm GmbH & Co. KG Multipartikuläre Arzneiform für wenig lösliche Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform
DE102004059792A1 (de) 2004-12-10 2006-06-14 Röhm GmbH & Co. KG Multipartikuläre Arzneiform, enthaltend mucoadhaesiv formulierte Nukleinsäure-Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform
CN100441166C (zh) * 2005-01-17 2008-12-10 闫彬 一种包含大黄和活性碳或药用碳的药物组合物
US9149439B2 (en) 2005-03-21 2015-10-06 Sandoz Ag Multi-particulate, modified-release composition
EP1883396B1 (en) 2005-05-18 2013-07-03 DA Volterra Colonic delivery of adsorbents
US8048413B2 (en) 2006-05-17 2011-11-01 Helene Huguet Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules

Also Published As

Publication number Publication date
CA2651569C (en) 2016-05-10
US20120107367A1 (en) 2012-05-03
EP2386308B1 (en) 2017-11-29
AU2007251565B2 (en) 2012-06-28
CN101969964A (zh) 2011-02-09
HUE036492T2 (hu) 2018-07-30
US8048413B2 (en) 2011-11-01
CN112891546A (zh) 2021-06-04
WO2007132022A3 (en) 2008-01-10
US20080031867A1 (en) 2008-02-07
US8388984B2 (en) 2013-03-05
EP2386308A1 (en) 2011-11-16
JP5829003B2 (ja) 2015-12-09
PL2386308T3 (pl) 2018-05-30
AU2007251565A1 (en) 2007-11-22
BRPI0712098B1 (pt) 2020-09-15
TR201802214T4 (tr) 2018-03-21
BRPI0712098B8 (pt) 2021-05-25
EP2026823A2 (en) 2009-02-25
PT2026823E (pt) 2014-06-25
BRPI0712098A2 (pt) 2012-01-17
PL2026823T3 (pl) 2014-10-31
DK2026823T3 (da) 2014-06-10
CA2651569A1 (en) 2007-11-22
ES2472703T3 (es) 2014-07-02
BRPI0712098A8 (pt) 2020-08-18
WO2007132022A2 (en) 2007-11-22
ES2660234T3 (es) 2018-03-21
JP2009537490A (ja) 2009-10-29
PT2386308T (pt) 2018-02-28
WO2007132022A8 (en) 2008-12-31
DK2386308T3 (da) 2018-03-05
EP2026823B1 (en) 2014-05-07

Similar Documents

Publication Publication Date Title
PL2026823T3 (pl) Ukierunkowane dojelitowe podawanie adsorbentów, samych lub w połączeniu z cząsteczkami powodującymi degradację
GB2449198B (en) Media delivery system with improved interaction
GB0602562D0 (en) Content Delivery
IL196019A0 (en) Associating advertisements with on-demand media content
GB2457189B (en) Multicasting push-to-media content
EP1934731A4 (en) CONTENT DELIVERY COMPATIBLE WITH THE DEVICE
EP2025123A4 (en) MULTICAST DELIVERY
GB0621973D0 (en) Binding molecules and uses thereof
IL184399A0 (en) Content delivery system
ZA200806492B (en) Binding molecules
IL198911A0 (en) Drug delivery
GB0621901D0 (en) Medicine delivery apparatus
ZA200902823B (en) Oligoribonucleotides and uses thereof
ZA200900494B (en) DNA Molecules and methods
EP2136846A4 (en) THERAPEUTIC OBJECTIVES AND MOLECULES
IL194751A0 (en) Drugs and uses
GB0618345D0 (en) Binding molecules
EP1902360A4 (en) SYSTEM FOR RELEASING CONTENT
EP2102365A4 (en) ENRICHMENT THROUGH HETERODUPLEX MOLECULES
GB2435420B (en) Delivery means
GB0709390D0 (en) Delivery means
GB0614160D0 (en) Decoding media Content
GB0615178D0 (en) Media content delivery process and means for achieving such
AU2007101262A4 (en) Improvements in cots
GB0620226D0 (en) Activated mesoporous carbon

Legal Events

Date Code Title Description
CHRG Changes in the register

Free format text: ADDITION OF INVENTORS: TSAPIS, NICOLAS - FATTAL, ELIAS

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20230518